Overview

Rheumocam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs and cats.

Rheumocam contains the active substance meloxicam and is a generic medicine. This means that Rheumocam contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the European Union (EU) called Metacam.

Cattle
In cattle, Rheumocam is used together with appropriate antibiotic therapy, to reduce clinical signs of acute respiratory infection (infection of the lungs and airways). It can be used with oral re-hydration therapy (medicines given by mouth to restore water levels in the body) to reduce diarrhoea in calves of over one week of age and young, non-lactating cattle. It can be used as supportive therapy in the treatment of acute mastitis (inflammation of the udder), in combination with antibiotics.

Pigs
In pigs, Rheumocam is used to reduce lameness and inflammation in non-infectious locomotor disorders (diseases that affect the ability to move), for the relief of post-operative pain after minor soft tissue surgery such as castration, and for supportive therapy together with appropriate antibiotic therapy in the treatment of diseases that occur after farrowing (giving birth) such as puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome). Septicaemia and toxaemia are conditions where bacteria circulate in the blood and produce harmful substances (toxins).

Horses
In horses, Rheumocam is used to reduce pain associated with colic (abdominal pain) and to lessen inflammation and relieve pain in acute and chronic musculo-skeletal disorders (disorders affecting the muscles and bones).

Dogs
In dogs, Rheumocam is used to reduce post-operative pain and inflammation following orthopaedic (e.g. fracture operation) and soft tissue surgery. Moreover, it is used to lessen inflammation and pain in acute and chronic musculo-skeletal disorders.

Cats
In cats, Rheumocam is used to reduce post-operative pain and inflammation after ovariohysterectomy (spaying operation), orthopaedic and minor soft tissue surgery. Moreover, it is used to lessen pain and inflammation in acute and chronic musculo-skeletal disorders.

Rheumocam is available as granules, an oral (taken by mouth) suspension, chewable tablets and a solution for injection. Injections may be into a vein, muscle or under the skin. The formulation to use depends on the animal and the condition being treated.

Rheumocam can only be obtained with a prescription. For further information about using Rheumocam, see the package leaflet or contact your veterinarian or pharmacist.

Rheumocam contains meloxicam, which belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). Meloxicam acts by blocking an enzyme called cyclo-oxygenase which is involved in the production of prostaglandins. As prostaglandins are substances that trigger inflammation, pain, exudation (fluid that leaks out of blood vessels during an inflammation) and fever, meloxicam reduces these signs of disease.

Since Rheumocam is a generic medicine, studies have been conducted to determine that it is bioequivalent to the reference medicine, Metacam. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

Because Rheumocam is a generic and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

Safety information has been included in the summary of product characteristics and the package leaflet for Rheumocam, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers. The precautions are the same as for the reference medicine since Rheumocam is a generic medicine.

The withdrawal period is the time required after administration of the medicine before an animal can be slaughtered and the meat used for human consumption. It is also the time required after administration of the medicine before milk may be used for human consumption.

Cattle
The withdrawal period for meat is 15 days and for milk it is five days.

 

Pigs
The withdrawal period for meat is five days.

Horses
The withdrawal period for meat is five days for the 20 mg/ml solution for injection and three days for the granules in sachet and 15 mg/ml oral suspension. The medicine is not authorised for use in horses producing milk for human consumption.

The European Medicines Agency concluded that, in accordance with EU requirements, Rheumocam has been shown to have comparable quality and to be bioequivalent to Metacam. Therefore the Agency’s view was that, as for Metacam, the benefits of Rheumocam, outweigh the identified risks and it can be authorised for use in the EU.

Rheumocam received a marketing authorisation valid throughout the EU on 10 January 2008.

Rheumocam : EPAR - Medicine overview

български (BG) (106.78 KB - PDF)
español (ES) (80.75 KB - PDF)
čeština (CS) (105.47 KB - PDF)
dansk (DA) (79.52 KB - PDF)
Deutsch (DE) (81.67 KB - PDF)
eesti keel (ET) (79.38 KB - PDF)
ελληνικά (EL) (114.27 KB - PDF)
français (FR) (81.48 KB - PDF)
hrvatski (HR) (97.27 KB - PDF)
italiano (IT) (80.09 KB - PDF)
latviešu valoda (LV) (108.85 KB - PDF)
lietuvių kalba (LT) (102.73 KB - PDF)
magyar (HU) (103.2 KB - PDF)
Malti (MT) (106.8 KB - PDF)
Nederlands (NL) (79.94 KB - PDF)
polski (PL) (103.96 KB - PDF)
português (PT) (80.75 KB - PDF)
română (RO) (100.85 KB - PDF)
slovenčina (SK) (104.08 KB - PDF)
slovenščina (SL) (94.45 KB - PDF)
Suomi (FI) (79.52 KB - PDF)
svenska (SV) (79.88 KB - PDF)

Product information

Rheumocam : EPAR - Product Information

български (BG) (869.37 KB - PDF)
español (ES) (671.83 KB - PDF)
čeština (CS) (732.58 KB - PDF)
dansk (DA) (736.9 KB - PDF)
Deutsch (DE) (683.22 KB - PDF)
eesti keel (ET) (652.56 KB - PDF)
ελληνικά (EL) (781.74 KB - PDF)
français (FR) (789.02 KB - PDF)
hrvatski (HR) (787.12 KB - PDF)
íslenska (IS) (652.33 KB - PDF)
italiano (IT) (769.7 KB - PDF)
latviešu valoda (LV) (715.89 KB - PDF)
lietuvių kalba (LT) (695.29 KB - PDF)
magyar (HU) (715.92 KB - PDF)
Malti (MT) (811.58 KB - PDF)
Nederlands (NL) (703.33 KB - PDF)
norsk (NO) (682.54 KB - PDF)
polski (PL) (859.17 KB - PDF)
português (PT) (787.32 KB - PDF)
română (RO) (759.5 KB - PDF)
slovenčina (SK) (826.12 KB - PDF)
slovenščina (SL) (711.49 KB - PDF)
Suomi (FI) (641.01 KB - PDF)
svenska (SV) (734.48 KB - PDF)

Latest procedure affecting product information: IB/0032/G

17/11/2021

Rheumocam : EPAR - All Authorised presentations

български (BG) (87.76 KB - PDF)
español (ES) (38.33 KB - PDF)
čeština (CS) (80.97 KB - PDF)
dansk (DA) (39.03 KB - PDF)
Deutsch (DE) (39.33 KB - PDF)
eesti keel (ET) (39.37 KB - PDF)
ελληνικά (EL) (89.45 KB - PDF)
français (FR) (38.04 KB - PDF)
hrvatski (HR) (76.96 KB - PDF)
íslenska (IS) (39.01 KB - PDF)
italiano (IT) (37.89 KB - PDF)
latviešu valoda (LV) (84.4 KB - PDF)
lietuvių kalba (LT) (82.04 KB - PDF)
magyar (HU) (80.28 KB - PDF)
Malti (MT) (82.32 KB - PDF)
Nederlands (NL) (40.64 KB - PDF)
norsk (NO) (55.39 KB - PDF)
polski (PL) (82.06 KB - PDF)
português (PT) (37.26 KB - PDF)
română (RO) (80.23 KB - PDF)
slovenčina (SK) (80.89 KB - PDF)
slovenščina (SL) (78.59 KB - PDF)
Suomi (FI) (38.78 KB - PDF)
svenska (SV) (41.53 KB - PDF)

Product details

Name of medicine
Rheumocam
Active substance
meloxicam
International non-proprietary name (INN) or common name
meloxicam
Species
  • Dogs
  • Horses
  • Cats
  • Cattle
  • Pigs
Anatomical therapeutic chemical veterinary (ATCvet) code
QM01AC06

Pharmacotherapeutic group

  • Oxicams
  • Anti-inflammatory and anti-rheumatic products, non-steroids

Therapeutic indication

Dogs
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. To reduce post-operative pain and inflammation following orthopaedic and soft tissue surgery.

Cats
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.

Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.

Cattle
For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

Pigs
For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy. For the relief of post operative pain associated with minor soft tissue such as castration.

Horses
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses..

For the relief of pain associated with equine colic.

Authorisation details

EMA product number
EMEA/V/C/000121

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Chanelle Pharmaceuticals Manufacturing Limited

Loughrea
Co. Galway
Ireland

Opinion adopted
15/07/2009
Marketing authorisation issued
10/01/2008
Revision
17

Assessment history

Rheumocam : EPAR - Procedural steps taken and scientific information after authorisation

Rheumocam-V-C-121-X-0022 : EPAR - Assessment Report - Extension

CVMP post-authorisation summary of positive opinion for Rheumocam (X-0022)

Rheumocam-V-C-121-X-0015 : EPAR - Assessment Report - Extension

CVMP post-authorisation summary of positive opinion for Rheumocam

Rheumocam-V-C-121-X-0010 : EPAR - Assessment Report - Extension

Rheumocam-V-C-121-X-0008 : EPAR - Assessment Report - Extension

CVMP post-authorisation summary of positive opinion for Rheumocam

Rheumocam-V-C-121-X-0007 : EPAR - Scientific Discussion - Extension

CVMP post-authorisation summary of positive opinion for Rheumocam

Rheumocam-V-C-121-X-0006 : EPAR - Scientific Discussion - Extension

CVMP post-authorisation summary of positive opinion for Rheumocam

Rheumocam : EPAR - Scientific Discussion

CVMP summary of opinion for Rheumocam

Rheumocam : EPAR - Procedural steps taken before authorisation

This page was last updated on

How useful do you find this page?